These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 28363434

  • 1. Switching biologics in the treatment of psoriatic arthritis.
    Merola JF, Lockshin B, Mody EA.
    Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
    [Abstract] [Full Text] [Related]

  • 2. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, Nott D, Liu-Leage S, Hartz S, Sapin C.
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWJ, Burmester GR, de Wit M, Falzon L, Landewé R.
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [Abstract] [Full Text] [Related]

  • 5. Novel approaches to biological therapy for psoriatic arthritis.
    Boyd T, Kavanaugh A.
    Expert Opin Biol Ther; 2016 Jun; 16(2):173-86. PubMed ID: 26572089
    [Abstract] [Full Text] [Related]

  • 6. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M, Teng GG, Cheung PP, Suresh E, Chia FL, Lui NL, Koh DR, Koh WH, Leong KP, Lim AYN, Ng SC, Thumboo J, Lau TC, Leong KH.
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P, Holko P, Moćko P, Pilc A.
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [Abstract] [Full Text] [Related]

  • 8. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rødevand E, Mikkelsen K, Lexberg AS, Kvien TK.
    Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R.
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [Abstract] [Full Text] [Related]

  • 10. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
    Lund Hansen R, Schoedt Jørgensen T, Dreyer L, Hetland ML, Glintborg B, Askling J, Di Giuseppe D, Jacobsson LTH, Wallman JK, Nordstrom D, Aaltonen K, Kristianslund EK, Kvien TK, Provan SA, Gudbjornsson B, Love TJ, Kristensen LE.
    Rheumatology (Oxford); 2021 Jan 05; 60(1):140-146. PubMed ID: 32591790
    [Abstract] [Full Text] [Related]

  • 11. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J, ARTIS Study group.
    Ann Rheum Dis; 2018 May 05; 77(5):650-657. PubMed ID: 29237621
    [Abstract] [Full Text] [Related]

  • 12. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž, Tomšič M, Praprotnik S, Slovenian Rheumatologists.
    Clin Rheumatol; 2019 Feb 05; 38(2):297-305. PubMed ID: 30324406
    [Abstract] [Full Text] [Related]

  • 13. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER.
    Ann Rheum Dis; 2022 Jan 05; 81(1):74-79. PubMed ID: 34281904
    [Abstract] [Full Text] [Related]

  • 14. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM, Chen DY.
    Expert Rev Clin Immunol; 2020 Feb 05; 16(2):207-228. PubMed ID: 31852268
    [Abstract] [Full Text] [Related]

  • 15. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N.
    Mod Rheumatol; 2015 Mar 05; 25(2):251-6. PubMed ID: 25211402
    [Abstract] [Full Text] [Related]

  • 16. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb 05; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

  • 17. Psoriatic arthritis: current therapy and future approaches.
    Huynh D, Kavanaugh A.
    Rheumatology (Oxford); 2015 Jan 05; 54(1):20-8. PubMed ID: 25125588
    [Abstract] [Full Text] [Related]

  • 18. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S, Kraus S, Schmidt S, Hueber A, Rech J, Engelke K, Englbrecht M, Schett G.
    Ann Rheum Dis; 2013 Jul 05; 72(7):1176-81. PubMed ID: 22915620
    [Abstract] [Full Text] [Related]

  • 19. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S, Thomas BJ, Ciurtin C.
    Rheumatol Int; 2016 May 05; 36(5):603-12. PubMed ID: 26892034
    [Abstract] [Full Text] [Related]

  • 20. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
    Lorenzin M, Ortolan A, Cozzi G, Calligaro A, Favaro M, Del Ross T, Doria A, Ramonda R.
    Clin Rheumatol; 2021 Nov 05; 40(11):4569-4580. PubMed ID: 34136971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.